Gilead Quad HIV Pill Tops Best-Selling Atripla in 48-Week Study
This article is for subscribers only.
Gilead Sciences Inc.’s four-in-one combination pill for AIDS was safer and more effective than its Atripla, the world’s top-selling HIV medicine, a study found.
After 48 weeks, the ‘quad’ pill reduced the virus to undetectable levels in 90 percent of patients, compared with 83 percent on Atripla, in the study released today. Side effects occurred in 46 percent of the quad patients, compared with 57 percent on the older drug, a combination of three medicines.